Welcome to our dedicated page for Vincerx Pharma news (Ticker: VINC), a resource for investors and traders seeking the latest updates and insights on Vincerx Pharma stock.
Vincerx Pharma, Inc. (VINC) generates news that reflects both its history as a clinical-stage oncology biopharmaceutical company and its more recent transition toward dissolution and liquidation. Earlier announcements describe Vincerx’s efforts to develop differentiated cancer therapies, including antibody-drug conjugates, a small molecule drug conjugate, a CDK9 inhibitor, a preclinical ADC, and the VersAptx bioconjugation platform. These disclosures provide context for news related to its pipeline and strategic collaborations.
More recent news coverage focuses on Vincerx’s corporate and capital markets developments. The company has issued multiple press releases about a Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of the company under a Plan of Liquidation and Dissolution. These releases detail adjournments of the meeting, the board’s unanimous recommendation that stockholders vote for the Dissolution Proposal, and estimated ranges of potential per-share distributions that could be available following approval, subject to assumptions and ongoing costs.
Other notable news items include Vincerx’s announcement of its intention to file a Form 25 to delist and deregister its common stock from The Nasdaq Stock Market, citing a Nasdaq delisting notice related to minimum bid price requirements and the board’s decision to dissolve and wind up the business. The company has also reported a 1-for-20 reverse stock split, terminations of binding term sheets and letters of intent for proposed mergers and reverse mergers, and the board’s evaluation of strategic alternatives such as out-licensing, asset sales, and potential wind-down.
Investors and observers following VINC news can expect updates on the status of the Dissolution Proposal, any changes to estimated distribution ranges, developments in the wind-down of operations, and regulatory or listing matters. Historical news also offers insight into Vincerx’s prior strategic merger discussions with Oqory, Inc. and its non-binding letter of intent with QumulusAI. This page serves as an archive of these corporate, strategic, and regulatory developments for Vincerx Pharma, Inc.
Vincerx Pharma presented positive results for its VIP152 treatment at the 2021 ASCO Annual Meeting, showcasing safety and efficacy in patients with double-hit lymphoma. Key findings included durable metabolic complete responses lasting over two years and a favorable safety profile, with no treatment discontinuations due to adverse effects. The ongoing Phase 1b expansion study aims to explore VIP152's potential further in challenging patient populations, including those with aggressive lymphomas and advanced solid tumors.
Vincerx Pharma announced promising data from its Phase 1 study of VIP152, a PTEFb/CDK9 inhibitor, presented at the 2021 ASCO Annual Meeting. The study showed favorable safety and efficacy in treating double-hit lymphoma, with no patients discontinuing due to adverse effects. Notably, durable metabolic complete responses were achieved, lasting over two years. The ongoing Phase 1b study aims to further explore VIP152's potential in aggressive lymphoma and advanced solid tumors. These developments emphasize Vincerx's commitment to addressing unmet cancer treatment needs.
Vincerx Pharma has successfully dosed its first patient in a Phase 1b clinical trial for VIP152, targeting MYC-driven aggressive lymphomas and advanced solid tumors. This milestone follows encouraging monotherapy signals from previous studies, highlighting a favorable safety profile and potential for durable disease control. The trial will enroll patients with relapsed or refractory aggressive lymphoma and those with advanced solid tumors exhibiting MYC overexpression. Vincerx plans to expand its clinical programs further in the coming months, aiming for multiple registration paths.
PALO ALTO, Calif., May 26, 2021 – Vincerx Pharma (Nasdaq: VINC) announced that its Chief Business Officer, Stuart Hwang, PhD, will present a corporate overview at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The specific presentation is scheduled for June 3, 2021, at 10:30 AM ET. Interested parties can watch the live webcast here. Vincerx focuses on developing innovative cancer therapies.
Vincerx Pharma reported significant progress in its clinical studies and financial results for Q1 2021. The FDA cleared the IND for VIP152, enabling a Phase 1b trial for patients with relapsed/refractory chronic lymphocytic leukemia, set to begin in 2H 2021. The company also expects to initiate dosing for MYC-driven cancers in Q2 2021. Financially, Vincerx ended Q1 with $53.4 million in cash, down from $61.8 million at the end of 2020, with a net loss of $6.3 million for the quarter.
Vincerx Pharma, Inc. (Nasdaq: VINC) announced the completion of its redemption event for outstanding public warrants on May 5, 2021. Approximately 99% of the 6,563,767 Public Warrants were exercised, generating $37.3 million in cash proceeds. The redemption price was set at $0.01 per warrant. A total of 17,505,239 shares of common stock were outstanding following the event. This move strengthens Vincerx's financial position as it focuses on advancing new cancer therapies through its pipeline, which includes an exclusive agreement with Bayer.
Vincerx Pharma announced FDA clearance for its Investigational New Drug application to initiate a Phase 1b dose escalation study of VIP152, a selective CDK9 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). This marks Vincerx's first IND clearance and second clinical program. The trial aims to enroll patients who failed prior treatments, with the study initiating in 2H 2021. Additionally, Vincerx is progressing in its first-in-human study for advanced cancers, set to begin patient dosing in Q2 2021.
Vincerx Pharma presented promising preclinical data for VIP236, a novel small molecule drug conjugate, at the AACR Annual Meeting 2021. This drug targets the αvβ3 integrin linked to a cytotoxic camptothecin derivative, showcasing enhanced tumor targeting and significant anti-tumor activity across various xenograft models. Specifically, complete tumor regression was observed in 100% of cases in a triple-negative breast cancer model. With first-in-human studies expected in the first half of 2022, VIP236 may address critical needs in aggressive cancer treatment.
PALO ALTO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma (Nasdaq: VINC) will host a key opinion leader (KOL) meeting on bioconjugation and CDK9 inhibitors on April 16, 2021, at 12:00 PM ET. KOLs Brian Druker, M.D., and Anthony W. Tolcher, M.D., will present and answer questions regarding advancements in cancer treatments. Vincerx will also discuss its novel small molecule drug conjugate targeting multiple cancers and its bioconjugation platform, which includes several promising candidates for hematologic tumors.
Vincerx Pharma announced the redemption of all outstanding public warrants to purchase its common stock, effective May 5, 2021. The redemption price is set at $0.01 per warrant. These warrants can be exercised until the redemption date, where unexercised warrants will become void. The company has met the criteria for redemption, as its stock price has consistently exceeded $16.50 for 20 trading days within the past 30 days. A total of 6,563,767 public warrants were issued, potentially raising approximately $37.7 million if fully exercised.
FAQ
What is the current stock price of Vincerx Pharma (VINC)?
What is the market cap of Vincerx Pharma (VINC)?
